Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209263 | 0.82 | DRD4 (0.37) | PPARGDRD4SLC40A1CETPABCB1 | |
| SCHEMBL7530200 | 0.78 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL4744464 | 0.77 | ATP4A (0.45) | DRD4CETP | |
| SCHEMBL4744045 | 0.77 | HRH3 (0.49) | SLC40A1CETPPOLB | |
| SCHEMBL17994186 | 0.76 | DRD4 (0.41) | PPARGDRD4SLC40A1CETPABCB1 | |
| SCHEMBL9005904 | 0.76 | DRD4 (0.46) | PPARGDRD4SLC40A1CETP | |
| SCHEMBL2786491 | 0.73 | PPARG (0.53) | PPARGPPARADRD4 | |
| SCHEMBL7922696 | 0.73 | PPARG (0.64) | PPARGPPARDDRD4 | |
| SCHEMBL9005955 | 0.72 | ALOX5 (0.47) | PPARGPPARADRD4SLC40A1 | |
| SCHEMBL9160316 | 0.72 | PPARG (0.42) | PPARGPPARADRD4SLC40A1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040102-B1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1194147-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1194146-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1040102-A4 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6465497-B2 | SUBSTITUTED 5-ARYL-2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES; AGONISTS OF PPAR (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR); USEFUL TREATING DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND OBESITY | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1194146-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6399640-B1 | ANTIDIABETIC AGENTS; ANTICHOLESTEROL AGENTS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| US-6380191-B1 | FOR TREATMENT, CONTROL OR PREVENTION OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA (INCLUDING HYPERCHOLESTEROLEMIA AND HYPERTRIGLYCERIDEMIA), ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO. INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1194146-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6200998-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS; ANTICHOLESTEROL, ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040102-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6008237-A | POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999032465-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037911-A1 | Substituted 5-aryl-2,4-thiazolidinediones and oxazolidinediones; agonists of PPAR (Peroxisome proliferator activated receptor); useful treating diabetes, hyperglycemia, hyperlipidemia, and obesity | PPARD, PPARA, PPARG | PPARG 3/4885PPARD 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.